Core Viewpoint - The new regulations from the National Medical Products Administration (NMPA) regarding traditional Chinese medicine (TCM) registration are set to significantly impact the industry, with over 70% of existing TCM products potentially facing elimination due to safety information issues in their labeling [1][5]. Regulatory Changes - The "death clause" in the new regulations mandates that any TCM product with unclear safety information in its labeling will not be approved for re-registration after July 1, 2026 [1]. - The NMPA has already begun implementing these regulations, requiring several commonly used TCM products to supplement core safety information for re-registration [2]. - A new set of regulations for TCM production supervision will take effect on March 1, 2026, raising industry entry barriers and imposing stricter requirements on the entire supply chain [2]. Industry Dynamics - The TCM industry is experiencing a stark divide between leading enterprises and smaller firms, with significant revenue disparities; for instance, the top company, Baiyunshan, reported revenues of 61.606 billion yuan, while smaller firms averaged around 6 million yuan [3]. - The cost of compliance for smaller firms is substantial, with estimates suggesting that a traditional TCM product may require an investment of at least 20 million yuan over three years to meet safety data requirements [3]. - Leading companies like Yunnan Baiyao and Tongrentang are proactively streamlining their product lines and focusing on core products backed by clinical data, while many smaller firms are left with limited options [3][4]. Market Trends - The regulatory changes are expected to lead to a significant increase in industry concentration, with predictions that leading firms will retain over 70% of their core products, while mid-tier companies may lose half of their approvals within two years [4]. - A nationwide price regulation initiative is underway, targeting low-quality TCM products and establishing minimum treatment costs for various medications [4]. - The dual approach of safety data requirements and price regulation is anticipated to further compress the market for low-quality TCM products, pushing the industry towards a focus on quality over quantity [5]. Strategic Responses - TCM companies are advised to pursue three main strategies: conducting real-world studies to enhance safety data, reclassifying promising products as improved new drugs, and voluntarily canceling low-value approvals to concentrate on core offerings [6]. - The future TCM market is expected to see heightened entry barriers, with products lacking safety data losing market access, and reimbursement mechanisms favoring clinically valuable products [6]. - The ongoing regulatory overhaul is viewed as an opportunity for the industry to shed low-quality products and focus on those that can withstand scientific scrutiny and gain patient trust [6].